(Q46817722)

25 December 2017

title

Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia (English)

1 reference

25 December 2017

1 reference

1 reference

Adam D Jaskiewicz

1

1 reference

25 December 2017

John D Herrington

series ordinal

2

1 reference

25 December 2017

Lucas Wong

series ordinal

3

1 reference

25 December 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

25 December 2017

published in

Pharmacotherapy

1 reference

25 December 2017

volume

25

1 reference

25 December 2017

issue

12

1 reference

25 December 2017

page(s)

1820-1825

1 reference

25 December 2017

Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1820

Tumor lysis syndrome: pathogenesis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1820

Adoptive chemoimmunotherapy using ex vivo activated memory T-cells and cyclophosphamide: tumor lysis syndrome of a metastatic soft tissue sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1820

Tumor lysis syndrome after combination chemotherapy for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1820

Tumor lysis syndrome in small cell carcinoma and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1820

Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1820

Primary plasma cell leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1820

Plasma cell leukemia: an evaluation of response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1820

Acute Tumor Lysis Syndrome in Hematologic Malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1820

Solitary plasmacytoma of bone and extramedullary plasmacytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1820

Proteasome inhibition: a novel approach to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1820

Proteasome inhibitors in the treatment of B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1820

Hematologic malignancies: new developments and future treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1820

Proteasome inhibition in cancer: development of PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1820

A method for estimating the probability of adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1820

Bortezomib is an efficient agent in plasma cell leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1820

10.1592/PHCO.2005.25.12.1820

21 January 2018

Identifiers

DOI

1 reference

25 December 2017

release_gnseusu32vcbznjwhlrmn4kgz4

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gnseusu32vcbznjwhlrmn4kgz4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

25 December 2017